Stocks tend to perform well in January, but that's not a good reason to invest this month. Strong returns aren't made in a ...

The last 12 months saw major regulatory changes for the field of gastroenterology, from new FDA approvals to sweeping statewide and national legislation. Here is what to know about a handful of recent ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday.Stay Ahead of the ...

北京时间2025年01月14日02时59分，精密科学（EXAS.us）股票出现异动，股价大幅上涨5.01%。截至发稿，该股报59.33美元/股，成交量114.698万股，换手率0.62%，振幅6.99%。 最近的财报数据显示，该股实现营业收入7.09亿美元，净利润-38.24百万美元，每股收益-0.21美元，毛利4.88亿美元，市盈率-51.02倍。 机构评级方面，在所有25家参与评级的机构中，8 ...

Exact Sciences' 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are ...

They’re non-invasive with none of the dreaded prep. But are recently approved home tests for colon cancer as effective as ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...